icrom

What icrom does

ICROM S.p.A. is an Italian chemical-pharmaceutical CDMO headquartered in Concorezzo (MB), Italy, founded in 1969 to manufacture active ingredients and GMP intermediates for the pharmaceutical industry. The company provides end-to-end custom development and manufacturing services for Active Pharmaceutical Ingredients (APIs), spanning from gram-scale laboratory work through clinical-scale batches up to multi-ton commercial production. Its 25-product commercial portfolio spans specialty and niche APIs including cytotoxics (e.g., Bortezomib, Paliperidone palmitate), sterile ophthalmics (Brinzolamide sterile, manufactured via proprietary patented technology), and diagnostic dyes (Fluorescein sodium, Indocyanine Green, Isosulfan Blue), with an additional pipeline of five development-stage APIs. ICROM is privately held under the Proxis Développement Group, an affiliate of the family-owned Protex International group, with the Moor family as controlling shareholders; CEO Pierfrancesco Morosini leads an executive team including a CFO, Operations Director, Quality Unit Director, R&D Director, HSE Director, and General Manager/Commercial Director.

ICROM's core technology rests on multi-scale chemical synthesis and GMP manufacturing of complex and high-tech molecules across four cGMP facilities with reactor capacity ranging from 25L to 6,000L (stainless steel and glass-lined) and a total reaction volume of approximately 100 m3. Differentiated capabilities include high-pressure catalytic hydrogenation (up to 10 Bar, 500L), cryogenic reactions down to -80°C in Hastelloy reactors, metal-catalyzed coupling reactions, ozonolysis, Grignard chemistry, polymorph and solid-state synthesis, and industrial radial-compression chromatography for purification of difficult compounds. A dedicated High-Potent API unit with two isolators handles cytotoxic and highly potent compounds, and a Clinical Scale Plant (completed 2022) supports small-scale GMP programs. The company is approved by US FDA, Japanese PMDA, Korean FDA, and Italian AIFA, holds Drug Master Files in all major regulated markets, and is GDUFA, REACH, ICH Q7, and Seveso Law compliant.

ICROM operates a B2B contract services business model, charging quote-based, project-tied fees for custom development, custom manufacturing, and commercial API supply to pharmaceutical and biotech customers across Europe, North America, Japan, China, India, the Middle East, and Latin America. Go-to-market is enterprise field sales supplemented by participation in industry events such as CPHI, DCAT Week, Bio Japan, and Bio Europe. The customer base spans global pharmaceutical companies and biotechnology firms with use cases including NCE custom synthesis, generic API supply, and cytotoxic/HPAPI manufacturing for injectables and ophthalmics. The company is pursuing expansion via THE CUBE large-scale production building (announced 2025), the October 2024 acquisition of French CRO Holodiag for solid-state and crystallization services, and new strategic partnerships with Patho-Logica (preclinical) and Spillo (technology tooling).

Name

icrom

Legal name

Icrom S.p.A.

Website

https://icrom.com

Company type

Private

Founded year

1969

Operating status

Operating

Headcount range

101–250 employees

Short description

ICROM is an Italian API CDMO offering custom development, GMP manufacturing, and commercial supply of specialty active pharmaceutical ingredients for pharmaceutical and biotech customers across 40+ countries. Founded in 1969 and headquartered in Concorezzo, it operates four cGMP facilities with multi-scale reactor capacity.

Ownership category

akta.pro rank

Product category

Pharmaceutical API Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (32541)

SIC

Miscellaneous Chemical Products (2890)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industry

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Active pharmaceutical ingredients
• GMP contract manufacturing
• Custom API development
• Pharmaceutical CDMO services
• API manufacturing intermediates

Headquarters

HQ city

Concorezzo

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Custom API Manufacturing: GMP manufacturing of Active Pharmaceutical Ingredients for pharmaceutical companies, ranging from clinical scale to commercial scale (grams to tons). Services include NCEs, generic APIs, and high-tech molecules.
2. Custom Development Services: Contract R&D services including process design, route discovery, multi-step synthesis, analytical development, and tech-transfer support.
3. Commercial API Sales: Sale of commercially available APIs from portfolio including cytotoxic compounds, specialty drugs, and diagnostic dyes for pharmaceutical applications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

ICROM is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) that develops and manufactures Active Pharmaceutical Ingredients (APIs) and GMP intermediates under cGMP. It provides custom process R&D and analytical development, GMP manufacturing from grams to tons scale for NCEs, generic APIs, and specialty drugs (including cytotoxic, highly potent, and sterile APIs), backed by specialized chemistry capabilities such as high-pressure hydrogenations, cryogenic reactions, ozonolysis, and metal-catalyzed couplings.

Product overview

ICROM is an API CDMO (Contract Development and Manufacturing Organization) offering a comprehensive suite of pharmaceutical manufacturing services. The company provides Custom Development Services (R&D and analytical development), Custom Manufacturing Services (GMP production across 4 facilities), APIs for Specialty Drugs (including cytotoxic and highly potent APIs), and Integrated Technologies (advanced chemistry capabilities). The commercial portfolio includes 25+ active pharmaceutical ingredients (Alizapride HCl, Amisulpride, Bepotastine Besilate, Bortezomib, Brinzolamide, Bromopride, Butizide, Diacerein, Epinastine HCl, Fluorescein sodium, Gliquidone, Indocyanine Green, Levosulpiride, Metoclopramide, Methylene Blue, Minoxidil, Paliperidone palmitate, Procaine HCl, Racecadotril, Risperidone, Sulpiride, Tiapride HCl) plus 5 new development candidates (Isavuconazonium sulfate, Isosulfan Blue, Regorafenib, Binimetinib, Encorafenib). Services range from grams to tons under GMP regulations.

Differentiator

Problem solved

Functional benefit

Products and services

• Custom Development Services Contract development services for pharmaceutical companies, including process design, custom synthesis of New Chemical Entities (NCEs), route discovery, multi-step synthesis, solid state chemistry, chiral chemistry, analytical method development, and impurity identification. The service is delivered from ICROM's R&D Unit (400 m², 16 hoods, glass reactors up to 10L, hydrogenator) and Analytical Development Unit (UPLC/MS, HPLC, GC, DSC, IR, titrators).
• Custom Manufacturing Services GMP manufacturing of APIs and intermediates for pharmaceutical companies across four GMP facilities with multi-scale capacity from 25L to 6,000L stainless steel and glass-lined reactors, Hastelloy cryogenic reactors, hydrogenation (500L, 10 Bar), particle size reduction, and a dedicated High-Potent Unit with two isolators for cytotoxic compounds. Production spans grams to tons scale under cGMP.
• APIs for Specialty Drugs

Quantifiable outcome

• Serves customers in more than 40 countries worldwide
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Four partnerships are on record, tiered core.

• HolodiagcoreStrategic or Co-development Partner · 21 October 2024ICROM acquired Holodiag, a French-based CRO specialized in solid state studies and crystallization services of small molecules. This acquisition aligns with ICROM Group's strategy to become a global leader CDMO for innovative as well as generic pharma space, enhancing their technology platform capabilities.
• Patho-LogicacoreStrategic or Co-development Partner · 2 September 2023Strategic partnership with Patho-Logica, an Israeli GLP accredited company delivering tailored pre-clinical solutions for Biotech, Pharma, Medical-Device and Diagnostic companies. The collaboration enables biopharmaceutical companies to streamline drug development through enhanced feasibility studies, accelerated project timelines, and increased product value by combining Patho-Logica's pre-clinical solutions with ICROM's adaptive pharmaceutical R&D and drug production capabilities.
• Proxis Développement GroupcoreOthersProxis Développement SA is a French industrial group founded in 2004, offering products, services and solutions across water treatment, perfumes, and agro-food sectors. ICROM is part of the group which consists of 4 business divisions: AQUAPROX, BIOPROX, ICROM, and SOZIO. The group is an affiliate of Protex International, an independent French Industrial Group founded in 1932, led by the Moor family for 3 generations.
• Protex InternationalcoreOthersProtex International is an independent French Industrial Group founded in 1932, headquartered in Paris. It has been run by the Moor family for 3 generations, currently leading a group of 300 million euros. ICROM became part of Protex International group in 1996 and later transferred to Proxis Développement group in 2004.

Scale indicators7 records

Recent moves12 records

Expansion highlights5 records

Direct peers

• Olon S.p.A. Italian-headquartered pure-play small-molecule API manufacturer and CDMO with multiple FDA-inspected sites. Directly comparable to ICROM in target customers (generic and innovative pharma), CDMO service model, complex-chemistry capabilities, and European base.
• Hovione: Portuguese family-owned API CDMO focused on highly potent and complex small molecules. Closely mirrors ICROM's boutique positioning, technology-driven differentiation (particle engineering, inhalation), and FDA-inspected global supply posture.
• Fabbrica Italiana Sintetici (F.I.S.): Italian API manufacturer and CDMO serving generic and innovative pharmaceutical customers worldwide. Same country, similar target customers, GMP manufacturing focus, and project-based CDMO service model as ICROM.
• Dipharma Francis S.r.l. Italian family-owned CDMO specializing in APIs and HPAPIs with FDA-inspected facilities. Competes with ICROM for the same high-potency, niche-molecule CMO contracts in Europe and the US.
• Seqens: French integrated CDMO providing custom API development and manufacturing with multiple cGMP sites. Comparable to ICROM in API CDMO services, European-base, FDA-inspected multi-site operations, and specialty chemistry.
• Cambrex: US-headquartered small-molecule API CDMO with FDA-inspected facilities serving innovator and generic pharma customers. Highly comparable service offering (process R&D and cGMP manufacturing) and customer profile to ICROM.
• Centrient Pharmaceuticals: Netherlands-based pure-play manufacturer of generic APIs (β-lactams and statins) with FDA, EMA, and PMDA approvals. Competes with ICROM in regulated generic API manufacturing and CDMO services for global pharmaceutical customers.

Broad incumbents

• EUROAPI: Large-scale API manufacturer spun out from Sanofi in 2022 with a broad portfolio across generics, HPAPIs, and CDMO services. Represents an incumbent alternative customers may select instead of ICROM, though its offering is broader and less differentiated.
• Johnson Matthey (Pharma Services): Diversified British chemicals group with a pharmaceutical API and catalyst CDMO division. Overlaps with ICROM in small-molecule API CDMO and complex chemistry but operates as part of a much larger, broader portfolio business.

Emerging players

• PolyPeptide Group: Switzerland-based CDMO specializing in peptide APIs and related complex chemistries for pharma customers. An adjacent rather than direct peer, but comparable as a European mid-sized specialty CDMO serving similar customer profiles.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/1190770

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about icrom